Compare Elevance Health Inc. Common Stock (ELV) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elevance Health Inc. Common Stock vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? Elevance Health Inc. Common Stock trades at $425.78 (market cap $92.23B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.81 (market cap $6.35B). The key difference: Elevance Health Inc. Common Stock is far larger — about 14.5× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays the higher dividend (9.8%). Which is the better fit depends on your goals — on Pluang, investors hold Elevance Health Inc. Common Stock for 1 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| ELV | OWL | |
|---|---|---|
Market Cap | $92.23B | $6.35B |
Volume | 1,842,737 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $428.09 | $17.17 |
52-Week Low | $280.74 | $8.23 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $113.04B | $10.53B |
Dividend Yield | 1.62% | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elevance Health (ELV) trades at $425.27, up 0.75% with a bullish technical outlook and strong institutional support. The stock shows consistent earnings beats with Q1 2026 EPS of $12.58 beating expectations by 16%, while maintaining solid fundamentals with $199.13B revenue and 11.2% ROE. Recent Medicare Advantage plan announcements and positive analyst coverage reinforce growth prospects.
ELV presents a compelling investment case with 71% analyst buy ratings and $445.13 price target offering 4.7% upside. However, declining 2026 profit margins to 2.46% and regulatory uncertainty in healthcare sector pose risks. The stock's current valuation at 18.81 P/E appears reasonable given earnings momentum and market position.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elevance Health Inc. Common Stock
Elevance Health provides health plans and healthcare services. Its offerings include medical, behavioral health, pharmacy, dental, vision, and complex-care solutions, including through the Carelon business.
Read more on ELV →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
